A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recent-onset Diagnosed Type 1 Diabetes (T1D)

NCT03751007 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes type1

Interventions

BIOLOGICAL: AG019 - Low Dose
DRUG: Teplizumab
DRUG: Placebo-AG019
DRUG: Placebo-Teplizumab
BIOLOGICAL: AG019 - High Dose
BIOLOGICAL: AG019 - High Dose

Sponsor

Precigen Actobio T1D, LLC

Collaborators

[object Object]